Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand ?
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease that results in progressive loss of motoneurons, motor weakness and death within 3-5 years after disease onset. Therapeutic options remain limited despite substantial number of approaches that have been tested clinically. Many neurotrophic growth factors are known to promote the survival of neurons and foster regeneration in the central nervous system. Various neurotrophic factors have been investigated pre-clinically and clinically for the treatment of ALS. Although pre-clinical data appeared promising, no neurotrophic factors succeeded yet in a clinical phase III trial. In this review we discuss the rationale behind those factors, possible reasons for clinical failures, and argue for a renewal of hope in this powerful class of drugs for the treatment of ALS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trk Receptors: Roles in Neuronal Signal Transduction
Huang, E. J., & Reichardt, L. F. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161629 · Cited by 2,537 · cited 1×
“Other effects are stimulation of neurite outgrowth and axon guidance (Tuttle and O’Leary, 1998; Huang and Reichardt, 2003), securing correct connectivity in the brain and spinal cord.”
BackgroundPurification of a new neurotrophic factor from mammalian brain.
Barde, Y. A., Edgar, D., & Thoenen, H. (1982) · The EMBO Journal · doi:10.1002/j.1460-2075.1982.tb01207.x · Cited by 1,822 · cited 1×
“BDNF is historically the second neurotrophic factor directly described as such (Barde et al., 1982).”
BackgroundTransport of brain-derived neurotrophic factor across the blood–brain barrier
Pan, W., Banks, W. A., Fasold, M. B., Bluth, J., & Kastin, A. J. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00141-5 · Cited by 1,354
Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations
Fisher, M., Feuerstein, G., Howells, D. W., Hurn, P. D., Kent, T. A., Savitz, S. I., & Lo, E. H. (2009) · Stroke · doi:10.1161/strokeaha.108.541128 · Cited by 1,352 · cited 1×
“In the field of stroke, this has been done by the so-called STAIR (Stroke Therapy Academic Industry Roundtable) criteria (Stroke Therapy Academic Industry Roundtable II (STAIR-II) 2001; Fisher, 2003; Fisher et al., 2005, 2007, 2009; Saver et al., 2009).”
MethodDirect brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons
Nagai, M., Re, D. B., Nagata, T., Chalazonitis, A., Jessell, T. M., Wichterle, H., & Przedborski, S. (2007) · Nature Neuroscience · doi:10.1038/nn1876 · Cited by 1,220
Nakamura, T., Nawa, K., & Ichihara, A. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91253-1 · Cited by 1,134
Molecular biology of amyotrophic lateral sclerosis: insights from genetics
Pasinelli, P., & Brown, R. H. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1971 · Cited by 1,107 · cited 1×
“From these data, and a wealth of pre-clinical and clinical investigations it is clear that the etiopathogenesis and pathophysiology of ALS is complex with many players involved that lead to the functional decline of the motor pathway (Pasinelli and Brown, 2006; Rothstein, 2009).”
BackgroundKaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067
Oosthuyse, B., Moons, L., Storkebaum, E., Beck, H., Nuyens, D., Brusselmans, K., Dorpe, J. V., Hellings, P., Gorselink, M., Heymans, S., et al. (2001) · Nature Genetics · doi:10.1038/88842 · Cited by 1,007
Cited by
BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases
Lu, B., Nagappan, G., Guan, X., Nathan, P. J., & Wren, P. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3505 · Cited by 743
A comprehensive review of amyotrophic lateral sclerosis
Zarei, S., Carr, K., Reiley, L., Diaz, K., Guerra, O., Altamirano, P., Pagani, W., Lodin, D., Orozco, G., & Chinea, A. (2015) · Surgical Neurology International · doi:10.4103/2152-7806.169561 · Cited by 709
ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?
Petrov, D., Mansfield, C., Moussy, A., & Hermine, O. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00068 · Cited by 451
“These include BDNF, CNTF, GDNF, IGF-1, VEGF, FGF; HGF, BMP-7, and G-CSF (for an excellent review of neurotrophic factors both in preclinical development and in CTs in ALS refer to Henriques et al. (2010).”
BackgroundImmune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies
Beers, D. R., & Appel, S. H. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30394-6 · Cited by 388
Moloney, E. B., de Winter, F., & Verhaagen, J. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00252 · Cited by 307
Metadata
- Authors
- Henriques
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2010
- Volume
- 4
- Pages
- 32-32
- ISSN
- 1662-453X (ISSN-L)
- OpenAlex
- W1987782076
- Cited by
- 115
- References
- 22
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand ? https://app.cochat.ai/papers/10.3389/fnins.2010.00032
- The paper
- Henriques. (2010). Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand ? Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2010.00032
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.